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The aim of this study was to evaluate the utility of pneumococcal urinary antigen detection
(Binax Now Streptococcus pneumoniae Antigen Test) in diagnosing pneumococcal exacerba-
tion of chronic obstructive pulmonary disease (COPD). Forty-six patients with S. pneumoniae
isolation in sputum culture were studied (29 collected in stable period and 17 collected
during exacerbation). In the 29 patients with samples collected in a stable period the antigen
was detected in 3 cases (10.3%) using nonconcentrated urine (NCU), and in 12 cases (41.4%)
using concentrated urine (CU). Regarding patients recruited during an exacerbation period,
the antigen was detected in 3 cases (17.6%) using NCU, and in 13 cases (76.5%) when CU
was used. For the evaluation of the specificity of the ICT test we also tested 72 cases in
which pneumococcus was not isolated in the sputum sample. ICT was positive in 1 NCU
and 9 CU of these patients. To have had at least one previous exacerbation (PZ 0.024), at
least one exacerbation that required hospitalization (PZ 0.027), and a pneumonia episode
in the year before (PZ 0.010) had statistically significant associated with the detection of
specific antigen in CU. Using NCU, the only significant association was found when a previouse Microbiologia, Fundacio´ Institut d’Investigacio´ en Cie`ncies de la Salut Germans Trias i Pujol,
lona, Barcelona, Spain. Tel.: þ34 934978894; fax: þ34 934978895.
(J. Domı´nguez).
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398 F. Andreo et al.pneumonia in the year before had occurred (PZ 0.006). In summary, a positive result of
pneumococcal urinary antigen from a COPD patient, in both bronchial exacerbation and
pneumonia, should be evaluated with caution because the antigen detected could be related
with previous infectious episode.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is defined
physiologically by the presence of irreversible or partially
reversible airway obstruction in patients with chronic
bronchitis and/or emphysema.1 Some patients with COPD
are prone to frequent exacerbations which are a major
cause of morbidity and mortality and an important
determinant of health related quality of life.2e4 Bacteria
cause a substantial proportion of exacerbations of COPD
which cause considerable morbidity and mortality.5e7
Bacteria are isolated from sputum in 40e60% of acute
exacerbations of COPD. The three predominant bacteria
species isolated are non-type Haemophilus influenzae,
Moraxella catarrhalis, and Streptococcus pneumoniae,
although Gram negative enteric bacilli, and Pseudomonas
spp are also frequently isolated in patients with severe
COPD.8 Several new lines of evidence demonstrate that
bacterial isolation from sputum during acute exacerbation
in many instances reflects a cause-effect relationship.4
Cultures of expectorated sputum from adults experi-
encing exacerbations of COPD reveal that S. pneumoniae
is isolated from 7 to 26% of such samples. However,
prevalence studies reveal that 20e40% of stable COPD
patients are colonized at any time by this microor-
ganism.7,9,10 Therefore, the isolation of S. pneumoniae
from sputum samples of chronic bronchitis patients only
provides a probable etiological diagnosis of the exacer-
bation. In addition, pneumococcus is not usually isolated
from the blood culture during exacerbation. At the
moment, a reliable method to distinguish between colo-
nization and clinical infection in COPD patients does not
exist.
In the last years, a new immunochromatographic (ICT) test
(Binax Now S. pneumoniae Antigen Test, Portland, Maine,
USA) was developed for detecting polysaccharide C (PnC) in
urine samples11e13 as well as serum14 and pleural fluid
samples.15 The test has proven rapid, sensitive and specific in
diagnosing pneumococcal pneumonia in adults.11,12,16
Furthermore, concentrating the urine by selective ultrafil-
trationmay elevate the utility of this test because it increases
sensitivity.17,18 The introduction of a S. pneumoniae urinary
antigen assay in clinical practice has increased the rate of the
etiological diagnosis of pneumococcal pneumonia.18
The aim of this study was to assess the performance of
the ICT method in diagnosing the pneumococcal bronchial
exacerbation of COPD, detecting specific urinary antigen.
Methods
Group of patients
We recruited prospectively COPD patients who attended to
Hospital Universitari Germans Trias i Pujol (Barcelona,Spain) and Hospital de Sant Boi de Llobregat (Barcelona,
Spain) for routine outpatients visits during a stable COPD
period, or for exacerbation of the disease. All patients met
standard criteria for the diagnosis of COPD.1 Ethics
approval for this study was provided by the Ethics
Committee of the Hospital Universitari Germans Trias i
Pujol, and of the Fundacio´ Jordi Gol i Gurina (Barcelona.
Spain). The severity of the disease was established by
means of the forced expiratory volume in one second (FEV1)
following the standard recommendations for the diagnosis
and treatment of patients with COPD.19 The clinical diag-
nosis of COPD exacerbation was defined as increased
breathlessness, and/or increased sputum volume, and/or
new or increased sputum purulence.20
Patients included in the study were analysed into groups
according to the fact that they were recruited during an
exacerbation or during a stable period of the disease, and
on the basis of the result of the sputum culture. Urine
samples were collected for S. pneumoniae antigen detec-
tion, being frozen at 20 C until testing.
The characteristics recorded for the patients included
in the study were the following: age, gender, smoking
status, underlying diseases, cor pulmonale, years since
evolution of COPD symptoms, basal dyspnoea, FEV1, clin-
ical symptoms, chest radiograph findings, microbiological
results, home oxygen therapy, and prior antibiotic and/or
steroid treatment. It was also recorded the number of
exacerbations and the number of exacerbations that
required hospitalization during the previous year, the
occurrence of a previous pneumonia episode, and antibi-
otic treatment. The basal treatment for COPD and infor-
mation about the evolution of the disease were also
recorded.
Patients that needed hospitalization to treat their
exacerbation followed conventional treatment based on
bronchodilators agents, systemic steroids, antibiotics and
oxygen therapy.
Inclusion criteria
COPD patients with FEV1< 80% after bronchodilators agents,
and/ airflow obstruction as evidenced by a ratio of FEV1 to
forced vital capacity (FVC)< 0.70were included in the study.
Exclusion criteria
The exclusion criteria were the following: patients with
clinical or radiological evidence of pneumonia at the
moment of diagnosis, or with documented pneumonia in
the previous two months, or with new chest radiographic
infiltrates in the following 48 h. Patients with history of
asthma, lung cancer causing airway obstruction, or other
significant respiratory disease, including active tubercu-
losis; patients vaccinated against S. pneumoniae within the
Table 1 General characteristics of patients with S.
pneumoniae isolated in the sputum culture (nZ 46).
Parameter N (%)
Age (years)
Mean and standard deviation 68.54 (10.18)
Gender
Female 1 (2.2)
Male 45 (97.8)
Smoking status
Active smoker 19 (41.3)
Ex-smoker 27 (58.7)
COPD status
Stable 29 (63)
Exacerbation 17 (37)
Underlying diseases
Yes 25 (54.3)
No 21 (45.7)
Heart failure 12 (48)
Hepatopathy 5 (20)
Diabetes 10 (40)
Cancer 5 (20)
Hematological disease 1 (4)
Neurological disease 3 (15)
Mild bronchiectasis 13 (52)
FEV1
Mean and standard deviation 1.004 (0.37)
FEV1 (%)
Mean and standard deviation 35.15 (11.96)
FEV1 (%)/FVC
Mean and standard deviation 50.57 (8.89)
Pneumococcal antigen detection in COPD 399previous month. Patients with immunosuppression defined
as HIV infection, leukopenia< 1000/mm3 or neu-
tropenia< 500/mm3, chronic treatment with steroids (
15 mg/day prednisone-equivalent during at least 3
months), immunosuppressor treatment in the 6 months
before, hypogammaglobulinemia, hypoasplenia, or
anatomic or functional asplenia, were also excluded.
Bacteriological culture
Gram’s staining and a standard bacteriological culture with
semi-quantification was done. For culturing, only good
quality sputum samples containing>25 polymorphonuclear
leukocytes and <10 squamous epithelial cells 100 field
were according to MurrayeWashington criteria accepted.21
Standard methods for culture and identification of micro-
organisms isolated from sputum culture were used.
Pneumococcal antigen detection
The presence of the PnC antigen of S. pneumoniae was
determined using the Binax ICT method. Frozen urine
samples were immediately thawed before the test. The
detection of pneumococcal antigen was performed in
nonconcentrated urine (NCU) and concentrated urine (CU)
by selective ultrafiltration.17 The samples were tested after
being stored between 1 and 9 months. ICT was performed
according to the instructions of the manufacturer. The
results were read visually in 15 min. The test was inter-
preted according to the presence or absence of visually
detectable pink-to-purple coloured lines.
Bacterial etiological exacerbation of COPD
The presumptive bacterial etiological diagnosis was deter-
mined when it complied with these criteria: 1) presence of
a clinical compatible picture; 2) presence of a predominant
type of microorganism after Gram staining and isolation of
a predominant type of respiratory pathogen in the culture
in sputum samples.
Radiological studies
In all cases of COPD exacerbation chest radiography was
performed and, in patients who required hospitalization,
serial chest radiography and thoracic computed tomog-
raphy were done during the evolution of the exacerbation
when it was necessary. The radiography from the previous
year was revised in order to rule out any possible pneu-
monia not detected.
Statistical analysis
We used the McNemar test to compare the results obtained
by the ICT test in NCU and CU. The differences in the ICT
results according to the different defined parameters
studied were calculated using Pearson Chi-squared test.
Differences were considered significant when the p value
was less than 0.05. All analyses were made with SPSS
statistical software for Windows (SPSS version 15.0; SPSS
Inc., Chicago; IL, USA).Results
We studied 46 patients (29 collected in stable period and 17
collected during exacerbation) who had a S. pneumoniae
isolated in the sputum culture. Table 1 shows the main
characteristics of these patients. From these patients it
was detected antigen in 6 cases using NCU, and in 25 cases
in CU. The overall number of positive results using CU was
significantly higher than using NCU (P< 0.0001).
In the 17 patients recruited during an exacerbation
period, the antigen was detected in 3 cases (17.6%) using
NCU, and in 13 cases (76.5%) when CU was used (Table 2).
Regarding the 29 patients in a stable period the antigen was
detected in 3 cases (10.3%) using NCU, and in 12 cases
(41.4%) using CU. The differences between the number of
positives using CU in patients during a stable period and
patients with exacerbation were also significant
(PZ 0.023). In contrast, this difference using NCU was not
significant (PZ 0.483).
For the evaluation of the specificity of the ICT test we also
tested 27 patients (13 in stable period and 14 during exac-
erbation) in which other predominant microorganism was
isolated in thesputumsample (7H. influenzae, 4 M.catarrhalis,
5 Pseudomonas aeruginosa, 1 P. aeruginosa and Aspergillus
fumigatus, 3 Staphylococcus aureus, 2 Escherichia coli, 1
Table 2 Pneumococcal urinary antigen detection in patients with COPD attending to the result of the sputum culture.
Result sputum culture Status COPD Positive pneumococcal urinary antigen detection
NCU (%) CU (%)
S. pneumoniae
Stable 3/29 (10.3) 12/29 (41.4)
Exacerbation 3/17 (17.6) 13/17 (76.5)
Other microorganisms than S. pneumoniae
Stable 0/13 (0) 2/13 (15.3)
Exacerbation 0/14 (0) 5/14 (35.7)
No predominant pathogen isolated
Stable 0/26 (0) 1/26 (3.8)
Exacerbation 1/19 (5.3) 1/19 (5.3)
400 F. Andreo et al.Citrobacter freundii, 1 Stenotrophomonas maltophilia, 1
Neisseria meningitidis, 1 Klebsiella pneumoniae, and 1
Enterobacter aerogenes); and45patients (26 in stableperiod
and 19 during exacerbation) in which a normal flora was
isolated from the sputum sample. The ICT was positive in
7 CU of patients with predominant pathogen in the sputum
culture (2 stable and 5 exacerbated patients), and in 1 NCU
(exacerbation) and 2 CU (1 stable and 1 exacerbation) of
patients without predominant pathogen (Table 2).
Using the result of the sputum culture as gold standard,
the sensitivity of the urinary antigen detection for diag-
nosing pneumococcal exacerbation in COPD patients using
NCU and CU was 17.6% and 76.5%, respectively; and the
specificity in exacerbated patients using NCU and CU was
96.9% (1/33) and 81.8% (6/33), respectively (Table 2).
The number of positive results was significantly higher in
patients with isolation of pneumococcus in the sputum
samples than in the other groups of patients (other patho-
gens and normal flora) in both NCU (PZ 0.024) and, CU
(P< 0.001) respectively.
Among all patients with isolation of S. pneumoniae in
the sputum sample, we found statistically significant asso-
ciation with the detection of specific antigen in CU, to be
younger than 65 yr (PZ 0.005), to have had at least one
previous exacerbation (PZ 0.024), at least one exacerba-
tion that required hospitalization (PZ 0.027), and patients
with a pneumonia episode within the previous year
(PZ 0.010). Using NCU the only significant association was
found with a previous pneumonia within the previous year
(PZ 0.006). However, the association was nearly significant
with previous exacerbation (PZ 0.057) and with exacer-
bation that required hospitalization (PZ 0.058).
When analysing the results of the stable patients,
statistically significant association was found with the fact
of being younger than 65 yr in NCU (PZ 0.038) and CU
(PZ 0.019), and with a previous case of pneumonia using
NCU (PZ 0.022). Regarding exacerbated patients, associ-
ation was found using CU in patients with previous inha-
lated steroids treatment (PZ 0.018) (Table 3).Discussion
Bacterial infection in COPD patients contributes signifi-
cantly in the pathogenesis and clinical evolution of thedisease.7,22 It has been described that patients who suffer
exacerbations have significantly lower health status.23,24
The development of reliable methods to define the etiology
of the infectious exacerbations will be definite for treating
adequately the patients. S. pneumoniae is one of the main
bacteria involved in exacerbation of the COPD patients.7
Detection of pneumococcal urinary antigen has been
presented as an alternative method for the diagnosis of
pneumococcal pneumonia in adults.11,16,18,25 In contrast,
its utility for diagnosing exacerbation of pneumococcal
etiology has not been extensively studied. Our results
showed that the ICT detects antigen, specially using CU, in
patients diagnosed of pneumococcal exacerbation by
means of sputum culture. Nevertheless, it was also possible
to detect antigen in patients during a stable period of the
disease, and also in patients that pneumococcus was not
isolated, both during exacerbation and during stable
period. In this sense, the detection of PnC antigen by ICT
does not allow to distinguish between colonization and
infection.
Although some potential cross-reactivity has been
described with few Streptococcus spp,26 the high clinical
specificity of the ICT test reported in previous
studies,11,12,25 and the fact that in our study the proportion
of positive results in patients with a S. pneumoniae isola-
tion in the sputum samples was statistically significant
higher than in the other group of patients, it allows us to
assume that the ICT test is detecting specific pneumococcal
antigen.
The result of the sputum culture during an exacerbation,
only gives a presumptive etiological diagnosis. Therefore,
we could not reject a real pneumococcal infection in
patients without S. pneumoniae isolation but with a posi-
tive ICT result. In addition, we could not be totally sure of
the pneumococcal etiology although the pneumococcus was
isolated in the sputum culture.
Positive results of pneumococcal urinary antigen detec-
tion in COPD patients without pneumonia have also been
reported. Murdoch DR et al.27 tested the ICT test in 97 NCU
of COPD patients, being in 49 cases collected during an
exacerbation, and in 48 cases during a stable period of the
disease. S. pneumoniae was isolated from nasopharyngeal
and/or sputum samples in 3 cases of exacerbated COPD
patients. Antigen was only detected in 3 cases of exacer-
bated patients. In only one of them, S. pneumoniae was
Table 3 Association between main characteristics of the COPD patients with S. pneumoniae isolation in the sputum samples, and the urinary antigen detection by means of
the immunochromatographic test.
Variables Number of positive results by ICT test
All patients Stable Exacerbation
NCU P CU P NCU P CU P NCU P CU P
Age
< 65 yr 3/11(27.3) 0.108 10/11(90.9) 0.005c 2/6 (33.3) 0.038c 5/6 (83.3) 0.019c 1/5 (20) 0.870 5/5 (100) 0.140
> 65 yr 3/35 (8.6) 15/35(42.9) 1/23 (4.3) 7/23(30.4) 2/12(16.7) 8/12(66.7)
Smoking status
Active smoker 3/18 (16.7) 0.432 11/18 (61.1) 0.346 2/11 (18.2) 0.241 6/11 (54.5) 0.210 1/7 (14.3) 0.761 5/7 (71.4) 0.682
Ex-smoker 4/28 (14.3) 15/28 (53.6) 1/18 (5.5) 6/18 (33.3) 2/10 (80) 8/10 (80)
Underlying disease
Yes 4/25 (16) 0.292 14/25 (56) 0.977 1/13 (7.7) 1 4/13 (30.8) 0.234 3/12 (25) 0.218 10/12 (83.3) 0.301
No 1/18 (5.6) 10/18(55.6) 1/13 (7.7) 7/13 (53.8) 0/5 (0) 3/5 (60)
Bronchiectasis
Yes 1/13 (7.7) 0.596 6/13 (46.2) 0.401 0/10 (0) 0.245 3/10 (30) 0.315 1/3 (33.3) 0.432 3/3 (100) 0.290
No 4/30(13.3) 18/30 (60) 2/16(12.5) 8/16 (50) 2/14(14.3) 10/14(71.4)
Prior inhaled steroid
Yes 4/34 (11.8) 0.376 20/34 (58.8) 0.247 1/21 (4.8) 0.699 8/21 (38.1) 0.873 3/13 (23.1) 0.356 12/13 (92.3) 0.018c
No 0/6 (0) 2/6 (33.3) 0/3 (0) 1/3 (33.3) 0/3 (0) 1/3 (33.3)
FEV1
< 35 5/25 (20) 0.224 16/25 (64) 0.375 2/14 (14.3) 0.636 7/14 (50) 0.671 3/11 (27.3) 0.243 9/11 (81.8) 0.770
> 35 1/16 (6.3) 8/8 (50) 1/12 (8.3) 5/12 (41.7) 0/4 (0) 3/4 (75)
Previous exacerbationa
Yes 5/19 (26.3) 0.057 8/21 (38.1) 0.024c 2/7 (28.6) 0.099 5/7 (71.4) 0.117 3/12 (25) 0.425 9/12 (75) 0.469
No 1/21 (4.8) 14/19 (73.7) 1/19 (5.3) 7/19 (36.8) 0/2 (0) 1/1 (50)
Hospitalizationa,b
Yes 4/16 (25) 0.058 12/16 (75) 0.027c 1/4 (25) 0.171 3/ 4 (75) 0.173 3/12 (25) 0.425 9/12 (75) 0.469
No 1/23 (4.3) 9/23 (39.1) 1/21 (4.8) 8/21 (38.1) 0/2 (0) 1/1 (50)
Previous pneumoniaa
Yes 3/7 (42.9) 0.006c 7/7 (100) 0.010c 1/ 2 (50) 0.022c 2/2 (100) 0.096 2/3 (40) 0.142 5/5 (100) 0.119
No 2/34 (5.9) 16/34 (47.1) 1/23 (4.3) 9/23 (39.1) 1/10 (10) 7/11 (63.6)
a In the year before.
b Exacerbation that required hospitalization.
c Differences were statistically significant.
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402 F. Andreo et al.isolated from respiratory samples. Therefore, the antigen
was detected in the 33.3% (1/3) of exacerbated patients
with isolated S. pneumoniae from respiratory samples, and
in the 4.3% (2/46) of exacerbated patients without
S. pneumoniae isolation. Indeed, the authors considered
interesting to repeat the study with a group of patients with
COPD who had a high rate of documented S. pneumoniae
colonization and/or infection. In our study, we studied
118 NCU of COPD patients, being in 50 cases collected
during an exacerbation process. The antigen was positive in
17.6% (3/17) of patients with isolated S. pneumoniae from
sputum samples, and in the 3% (1/33) of patients without
S. pneumoniae isolation. Although the overall results are
similar in exacerbated patients in comparison with the
Murdoch et al.27 study, they did not detected positive
results in stable patients. However, in only one case of the
48 patients recruited in a stable period S. pneumoniae was
isolated from respiratory samples. In contrast, in our study
we have studied 29 cases, obtaining positive results in 3 of
them.
There are some theories and hypothesis for justifying
the results obtained in patients during a stable period.
On the one hand, the persistent colonization of the respi-
ratory mucosa with S. pneumoniae could be responsible of
the detection of pneumococcal antigen in urine. It has been
proven that ICT test is not useful for diagnosing pneumonia
in children. The colonization by S. pneumoniae in the
nasopharynx in children, specially under 2 years old,
induces positive pneumococcal urinary antigen detec-
tion.28,29 In COPD patients S. pneumoniae is frequently
recovered from the sputum, even in the absence of clinical
infection.7 Therefore, in the lower airways of adults with
COPD colonized with S. pneumoniae, there are continuous
division and shedding of cell wall fragments into the
airways.7 These antigens could be cleared from the airways
by the immune system and released finally by the urine.
On the other hand the presence of the S. pneumonie
antigen in urine samples could represent a low grade
infection. In fact, in some cases, in the routinely medical
controls, patients underestimate the symptoms. In this case
the early detection of antigen could be a benefit for
patients. This potential explanation requires further
investigation to be validated.
On the other hand, it has also been described the long
persistence of specific pneumococcal antigen in urine after
a pneumococcal pneumonia.18,25,27,30 It has been described
in a previous study that in a pneumococcal pneumonia the
lung may contain up to 2 g or even more capsular poly-
saccharide.31 The release of large amounts of antigen from
the lung to the bloodstream and their total clearance from
the human body will require a long time. In our experience,
it is possible to detect antigen more than 6 months after
the diagnosis of pneumonia.30 COPD is the most common
underlying disease in patients with pneumonia, being COPD
a frequent condition associated with the development of
pneumonia. S. pneumoniae has been described as the
leading cause of community-acquired pneumonia in COPD
patients.32 It is also possible that, after an acute pneumo-
coccal exacerbation of the COPD, the time of excretion of
the antigen could be also long. In fact, previous exacer-
bation episodes have been associated with the fact of
obtaining a positive ICT test.The main limitation of the current evaluation is that we
studied a small group of patients. This fact could influence
the statistical analysis and avoid performing multivariate
analysis. Despite this limitation, our study provides rele-
vant data related to the clinical utility of the PnC antigen
detection by ICT in urine samples in COPD patients. Even
thought, further studies including more patients could be
adequate for confirming the results.
In summary, although the test was able to detect pneu-
mococcal antigen during an exacerbation, it was also
possible to detect antigen during stable period. Therefore, it
may be difficult to consider the test as a reliable method for
diagnosing pneumococcal exacerbation. This fact could be
due to a previous exacerbation and or pneumonia episode
and with the long time excretion of antigen by the urine.
Consequently, its utilization for diagnosing pneumococcal
exacerbation or pneumonia in COPD patients should be also
used cautiously, because the antigen detected could be
residual and not being related to the present episode.
Longitudinal studies should be considered in the future for
providing additional information in this issue.
Acknowledgements
We thank the nurse and nurses’ aides staff of the Hospital
de Sant Boi and the Hospital Universitari Germans Trias i
Pujol for technical assistance.Financial support
This work was supported by a grant from the Societat
Catalana de Pneumologia (SOCAP) and the Fundacio´
Catalana de Pneumologia (FUCAP).
Conflicts of interest
None of the investigators have any financial interest in
or a financial conflict with the subject matter or
materials discussed in this manuscript. None of the
Scientific Societies, neither Binax Inc. (Portland,
Maine, USA) had a role in the study design, conduct,
collection, management, analysis, or interpretation of
the data, or preparation, review, or approval of the
manuscript.
References
1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS.
Global strategy for the diagnosis, management, and prevention
of chronic obstructive pulmonary disease. NHLBI/WHO global
initiative for chronic obstructive lung disease (GOLD) workshop
summary. Am J Respir Crit Care Med 2001;163:1256e76.
2. Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors
to bacterial colonization in chronic obstructive pulmonary
disease. Eur Respir J 1999;13:343e8.
3. Monso E, Rosell A, Bonet G, et al. Risk factors for lower airway
bacterial colonization in chronic bronchitis. Eur Respir J 1999;
13:338e42.
4. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstruc-
tive pulmonary disease. Proc Am Thorac Soc 2007;4:554e64.
Pneumococcal antigen detection in COPD 4035. Stockley RA. Lung infections. 1. Role of bacteria in the path-
ogenesis and progression of acute and chronic lung infection.
Thorax 1998;53:58e62.
6. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC,
Wedzicha JA. Relationship between bacterial colonisation and
the frequency, character, and severity of COPD exacerbations.
Thorax 2002;57:759e64.
7. Sethi S, Murphy TF. Bacterial infection in chronic obstructive
pulmonary disease in 2000: a state-of-the-art review. Clin
Microbiol Rev 2001;14:336e63.
8. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic
obstructive pulmonary disease. A study of stable and exacer-
bated outpatients using the protected specimen brush. Am J
Respir Crit Care Med 1995;152:1316e20.
9. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H.
Infective exacerbations of chronic bronchitis: relation between
bacteriologic etiology and lung function.Chest 1998;113:1542e8.
10. Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA,
Maldonado JA, Gallego M. Relationship between bacterial flora
in sputum and functional impairment in patients with acute
exacerbations of COPD. Study group of bacterial infection in
COPD. Chest 1999;116:40e6.
11. Dominguez J, Gali N, Blanco S, et al. Detection of Strepto-
coccus pneumoniae antigen by a rapid immunochromato-
graphic assay in urine samples. Chest 2001;119:243e9.
12. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid
immunochromatographic test for detection of Streptococcus
pneumoniae antigen in urine samples from adults with commu-
nity-acquired pneumonia. J Clin Microbiol 2001;39:3495e8.
13. Roson B, Fernandez-Sabe N, Carratala J, et al. Contribution of
a urinary antigen assay (Binax NOW) to the early diagnosis of
pneumococcal pneumonia. Clin Infect Dis 2004;38:222e6.
14. Dominguez J, Andreo F, Blanco S, et al. Rapid detection of
pneumococcal antigen in serum samples for diagnosing pneu-
mococcal pneumonia. J Infect 2006;53:21e4.
15. Andreo F, Dominguez J, Ruiz-Manzano J, et al. Usefulness of
pneumococcal antigen detection in pleural fluid samples by
immunochromatographic assay for diagnosis of pneumococcal
pneumonia. Clin Microbiol Infect 2006;12:682e4.
16. Gutierrez F, Masia M, Rodriguez JC, et al. Evaluation of the
immunochromatographic Binax NOW assay for detection of
Streptococcus pneumoniae urinary antigen in a prospective
study of community-acquired pneumonia in Spain. Clin Infect
Dis 2003;36:286e92.
17. Blanco S, Prat C, Pallares MA, Matas L, Dominguez J. Centrifugal
ultrafiltration method for rapid concentration of Legionella
pneumophila urinary antigen. J Clin Microbiol 2004;42:4410.18. Andreo F, Dominguez J, Ruiz J, et al. Impact of rapid urine
antigen tests to determine the etiology of community-acquired
pneumonia in adults. Respir Med 2006;100:884e91.
19. Celli BR, MacNee W. Standards for the diagnosis and treatment
of patients with COPD: a summary of the ATS/ERS position
paper. Eur Respir J 2004;23:932e46.
20. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES,
Harding GK, Nelson NA. Antibiotic therapy in exacerbations of
chronic obstructive pulmonary disease. Ann Intern Med 1987;
106:196e204.
21. Murray PR, Washington JA. Microscopic and baceriologic anal-
ysis of expectorated sputum. Mayo Clin Proc 1975;50:339e44.
22. Rosell A, Monso E, Soler N, et al. Microbiologic determinants of
exacerbation in chronic obstructive pulmonary disease. Arch
Intern Med 2005;165:891e7.
23. White AJ, Gompertz S, Stockley RA. Chronic obstructive
pulmonary disease. 6: the aetiology of exacerbations of chronic
obstructive pulmonary disease. Thorax 2003;58:73e80.
24. Veeramachaneni SB, Sethi S. Pathogenesis of bacterial exac-
erbations of COPD. COPD 2006;3:109e15.
25. Marcos MA, Jimenez de Anta MT, de la Bellacasa JP, et al.
Rapid urinary antigen test for diagnosis of pneumococcal
community-acquired pneumonia in adults. Eur Respir J 2003;
21:209e14.
26. Werno AM, Murdoch DR. Medical microbiology: laboratory
diagnosis of invasive pneumococcal disease. Clin Infect Dis
2008;46:926e32.
27. Murdoch DR, Laing RT, Cook JM. The NOW S. pneumoniae
urinary antigen test positivity rate 6 weeks after pneumonia
onset and among patients with COPD. Clin Infect Dis 2003;37:
153e4.
28. Dominguez J, Blanco S, Rodrigo C, et al. Usefulness of urinary
antigen detection by an immunochromatographic test for
diagnosis of pneumococcal pneumonia in children. J Clin
Microbiol 2003;41:2161e3.
29. Faden H, Heimerl M, Varma C, Goodman G, Winkelstein P.
Urinary excretion of pneumococcal cell wall polysaccharide in
children. Pediatr Infect Dis J 2002;21:791e3.
30. Andreo F, Prat C, Ruiz J, et al. Persistence of Streptococcus
pneumoniae urinary antigen excretion after pneumococcal
pneumonia. Eur J Clin Microbiol 2008;28:197e201.
31. Coonrod JD, Drennan DP. Pneumococcal pneumonia: capsular
polysaccharide antigenemia and antibody responses. Ann
Intern Med 1976;84:254e60.
32. Torres A, Dorca J, Zalacain R, et al. Community-acquired pneu-
monia in chronic obstructive pulmonary disease: a Spanish
multicenter study.Am J Respir Crit Care Med 1996;154:1456e61.
